High levels of NK Cells in graft are associated with reduced febrile neutropenia after haploidentical peripheral blood stem cell transplantation
- PMID: 37480280
- PMCID: PMC10363871
- DOI: 10.1177/03000605231187932
High levels of NK Cells in graft are associated with reduced febrile neutropenia after haploidentical peripheral blood stem cell transplantation
Abstract
Objective: To investigate the impact of natural killer (NK) cells in the graft on the outcome following haploidentical peripheral blood stem cell transplantation (haplo-PBSCT).
Methods: We retrospectively collected data from patients who had undergone haplo-PBSCT at our centre from January 2019 to November 2021. The percentage of NK cells in stem cell grafts was detected by flow cytometry. Based on the median (range) count of NK cells (1.8 [0.4-6.0] × 108/kg), patients were separated into high and low NK cell count groups.
Results: Data from 96 patients were analysed. Patients were evenly distributed (48 in each group) into high and low NK cell count groups. There was no significant difference in neutrophil and platelet recovery between the two groups. However, the rates of febrile neutropenia, bacterial infection, and invasive fungal disease (IFD) were significantly reduced in the high compared with the low NK cell count group. There was no significant difference in rates of cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections between groups. There was no significant difference between groups in grades II and above acute graft versus host disease (GVHD), progression-free survival (PFS), or overall survival (OS).
Conclusion: A high number of NK cells in the graft may reduce febrile neutropenia, IFD and bacterial infection following haplo-PBSCT but it has no significant effect on aGVHD, PFS, or OS.
Keywords: Haploidentical peripheral blood stem cell transplantation; NK cells; febrile neutropenia; haplo-PBSCT.
Conflict of interest statement
The authors declare that there are no conflicts of interest.
Figures

Similar articles
-
Optimal Active Anti-Thymocyte Globulin Exposure Associated with Minimum Risk of Virus Reactivation and Comparable Acute Graft-Versus-Host Disease Under Adult Myeloablative Haploidentical Peripheral Blood Stem Cell Transplantation.Transplant Cell Ther. 2022 Jun;28(6):332.e1-332.e10. doi: 10.1016/j.jtct.2022.03.018. Epub 2022 Mar 18. Transplant Cell Ther. 2022. PMID: 35314377
-
Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies.Biol Blood Marrow Transplant. 2016 Nov;22(11):2047-2055. doi: 10.1016/j.bbmt.2016.08.003. Epub 2016 Aug 10. Biol Blood Marrow Transplant. 2016. PMID: 27522040
-
Pre-infusion single-dose mesenchymal stem cells promote platelet engraftment and decrease severe acute graft versus host disease without relapse in haploidentical peripheral blood stem cell transplantation.J Int Med Res. 2020 May;48(5):300060520920438. doi: 10.1177/0300060520920438. J Int Med Res. 2020. PMID: 32363972 Free PMC article. Clinical Trial.
-
Lower Absolute Lymphocyte Count Before Conditioning Predicts High Relapse Risk in Patients After Haploidentical Peripheral Blood Stem Cell Transplantation With Low Dose Anti-Thymocyte Globulin/Post-Transplant Cyclophosphamide for GvHD Prophylaxis.Cell Transplant. 2022 Jan-Dec;31:9636897221079739. doi: 10.1177/09636897221079739. Cell Transplant. 2022. PMID: 35225024 Free PMC article.
-
Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide: A Systematic Review and Meta-Analysis Comparing Myeloablative with Reduced-Intensity Conditioning Regimens and Bone Marrow with Peripheral Blood Stem Cell Grafts.Transplant Cell Ther. 2021 Sep;27(9):782.e1-782.e7. doi: 10.1016/j.jtct.2021.06.011. Epub 2021 Jun 16. Transplant Cell Ther. 2021. PMID: 34146733
References
-
- Gu G, Yang JZ, Sun LX.Correlation of graft immune composition with outcomes after allogeneic stem cell transplantation: Moving towards a perfect transplant. Cell Immunol 2018; 323: 1–8. - PubMed
-
- Stikvoort A, Gaballa A, Solders M, et al.. Risk Factors for Severe Acute Graft-versus-Host Disease in Donor Graft Composition. Biol Blood Marrow Transplant 2018; 24: 467–477. - PubMed
-
- Svenberg P, Wang T, Uhlin M, et al.. The importance of graft cell composition in outcome after allogeneic stem cell transplantation in patients with malignant disease. Clin Transplant 2019; 33: e13537. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources